Emerging Agents in Small Cell Lung Cancer | IASLC
Small cell lung cancer is a challenging subtype of lung cancer to treat because most patients present with extensive stage disease. Unlike non-small cell lung c …
Small cell lung cancer is a challenging subtype of lung cancer to treat because most patients present with extensive stage disease. Unlike non-small cell lung c …
An abstract is unavailable.
Even if you’re in remission or you show no evidence of disease, you may still have fears that cancer may return. We spoke with our…
Setanaxib plus pembrolizumab improved progression-free survival and overall survival in recurrent or metastatic head and neck squamous cell carcinoma.
Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer.
A quarterly newsletter for patients living with cancer, survivors, advocates and consumers
Class sizes are limited and you must be registered to participate. Please do not share links or class materials with others. See map below for…
Nearly 25 years after arriving at Fred Hutch Cancer Center for his hematology-oncology fellowship, Bart Scott, MD, has been named the Miklos Kohary and Natalia…
During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that looked at outcomes of dose optimization of regorafenib for patients with…
Changchun Deng, MD, PhD, discusses factors to consider when sequencing covalent BTK inhibitors and venetoclax in patients with CLL/SLL.